These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16544387)

  • 1. Response to expression of concern regarding VIGOR study.
    Reicin A; Shapiro D
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16544387
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to expression of concern regarding VIGOR study.
    Bombardier C; Laine L; Burgos-Vargas R; Davis B; Day R; Ferraz MB; Hawkey CJ; Hochberg MC; Kvien TK; Schnitzer TJ; Weaver A
    N Engl J Med; 2006 Mar; 354(11):1196-9. PubMed ID: 16495387
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of concern reaffirmed.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2006 Mar; 354(11):1193. PubMed ID: 16495386
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lessons of Vioxx--drug safety and sales.
    Waxman HA
    N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
    [No Abstract]   [Full Text] [Related]  

  • 6. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 7. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rofecoxib (Vioxx) has been withdrawn, what next?].
    Idänpään-Heikkilä JE; Klaukka T
    Duodecim; 2004; 120(21):2489-90. PubMed ID: 15631403
    [No Abstract]   [Full Text] [Related]  

  • 9. [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
    Kellner H
    Z Gastroenterol; 2001 May; 39(5):443-5. PubMed ID: 11413920
    [No Abstract]   [Full Text] [Related]  

  • 10. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
    MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
    [No Abstract]   [Full Text] [Related]  

  • 11. The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor.
    Warner JJ; Weideman RA; Kelly KC; Brilakis ES; Banerjee S; Cunningham F; Harford WV; Kazi S; Little BB; Cryer B
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):252-60. PubMed ID: 18787084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
    Lynd LD; Marra CA; Najafzadeh M; Sadatsafavi M
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1172-80. PubMed ID: 20602338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational studies and the withdrawal of rofecoxib.
    Watson DJ; Santanello NC
    Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
    [No Abstract]   [Full Text] [Related]  

  • 14. Discontinuation of Vioxx.
    Lièvre M; Abadie E;
    Lancet; 2005 Jan 1-7; 365(9453):23-4; author reply 26-7. PubMed ID: 15639668
    [No Abstract]   [Full Text] [Related]  

  • 15. Lapses at the new England journal of medicine.
    Smith R
    J R Soc Med; 2006 Aug; 99(8):380-2. PubMed ID: 16893926
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rofecoxib increases myocardial infarction risk in seniors].
    Wasielewski S
    Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
    [No Abstract]   [Full Text] [Related]  

  • 17. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased risk of cardiovascular events with coxibs and NSAIDs.
    Emery P; Moore A; Hawkey C
    Lancet; 2005 Apr 30-May 6; 365(9470):1538. PubMed ID: 15866301
    [No Abstract]   [Full Text] [Related]  

  • 19. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seeds of doubt--ADVANTAGE no one.
    Jackson G
    Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.